Medtronic Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Announces 9% Dividend Increase

Go back to Medtronic Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Announces 9% Dividend Increase

Medtronic, Inc. (MDT) PT Raised to $147 at Oppenheimer

May 28, 2021 9:50 AM EDT

Oppenheimer analyst Steven Lichtman raised the price target on Medtronic, Inc. (NYSE: MDT) to $147.00 (from $134.00) while maintaining an Outperform rating following fourth quarter results.

The analyst commented, "On its F4Q21 call, MDT highlighted continued COVID-19 procedural recovery and solid sales outlook. Key updates: 1) monthly... More

Medtronic (MDT) Tops Q4 Earnings Estimates, Announces 'Largest Ever' R&D Spending to Support Growth

May 27, 2021 10:20 AM EDT

Shares of Medtronic (NYSE: MDT) are up 0.5% in todays trading session after the company reported better-than-expected earnings for its fourth quarter.

The company reported adjusted earnings per share (EPS) of $1.50 per share on $8.19 billion in sales, which compares to EPS of $1.42 a share on $7.86 billion in sales expected from the surveyed market analysts.

"We reported a strong end to our fiscal year, with our fourth quarter results demonstrating continued momentum. Our recovery improved throughout the quarter, with most of our markets returning to near normal, pre-COVID... More

Medtronic (MDT) Tops Q4 EPS by 8c, Offers FY22 Guidance, Raises Dividend

May 27, 2021 6:46 AM EDT

(Updated - May 27, 2021 6:50 AM EDT)

Medtronic (NYSE: MDT) reported Q4 EPS of $1.50, $0.08 better than the analyst estimate of $1.42. Revenue for the quarter came in at $8.2 billion versus the consensus estimate of $8.14 billion.

GUIDANCE:

Medtronic sees 2022 EPS of $5.60-$5.75, versus the consensus of $5.72.

The company expects revenue growth in its fiscal year 2022 to approximate 9 percent on an organic basis. If current exchange rates hold, revenue growth in fiscal year 2022 would be positively affected by approximately $400 to $500 million."Our fiscal 2022 revenue guidance that we... More